Eli Lilly Reports Strong Q1 2024 Results and Raises Guidance
Tuesday, 30 April 2024, 18:30
Eli Lilly's Q1 2024 Earnings Call Highlights:
- Revenue grew by 26% in Q1, with new products driving growth.
- Key pipeline milestones include positive phase 3 results for tirzepatide and approvals for new delivery devices.
- Ambitious manufacturing expansion plans to meet demand and increase supply capacity.
- Increased guidance reflecting confidence in capacity expansion progress.
Conclusion:
Eli Lilly's strong performance in Q1 2024, driven by revenue growth, pipeline advancements, and manufacturing capacity expansion initiatives, positions the company for continued success and growth in the pharmaceutical market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.